Expert Opin Investig Drugs. 2009 Jan;18(1):31-43.

Development of PARP inhibitors in oncology.

Source

UT MD Anderson Cancer Center, Investigational Cancer Therapeutics, (Unit 455), 1515 Holcombe Blvd, Houston, TX 77030, USA. jrodonahnert@gmail.com

Abstract

Poly (ADP-ribose) polymerase (PARP) plays a key role in DNA repair mechanisms by detecting and initiating repair after DNA strand breaks. Inhibition of PARP in DNA repair-defective tumors (like those with BRCA1 or BRCA2 mutations) can lead to gross genomic instability and cell death. Likewise, combining PARP inhibition with cytotoxic agents such as chemotherapy or radiation therapy is synergistic in many preclinical models. Several drugs designed to inhibit PARP are currently in clinical development, many following a development path different from that of typical anticancer agents. In this review we will focus on the early clinical data from PARP inhibitors that are entering clinical trials, the potential tumors they might target, their combination with other drugs and the different biomarkers that are being explored. Concepts such as 'BRCAness', synthetic lethality, Phase 0 trials and pharmacodynamic markers will be discussed in the context of the development of PARP inhibitors.

PMID:: 19053880; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

[PARP inhibitors for cancer therapy]. [Gan To Kagaku Ryoho. 2011]
[PARP inhibitors for cancer therapy].
Saito H, Miki Y. Gan To Kagaku Ryoho. 2011 Jan; 38(1):12-8.
Review Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. [Eur J Cancer. 2010]
Review Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Sandhu SK, Yap TA, de Bono JS. Eur J Cancer. 2010 Jan; 46(1):9-20.
Review PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. [Drug Resist Updat. 2009]
Review PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Drew Y, Plummer R. Drug Resist Updat. 2009 Dec; 12(6):153-6. Epub 2009 Nov 25.
Review PARP inhibitor development for systemic cancer targeting. [Anticancer Agents Med Chem. 2007]
Review PARP inhibitor development for systemic cancer targeting.
Zaremba T, Curtin NJ. Anticancer Agents Med Chem. 2007 Sep; 7(5):515-23.
Review Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment. [Clin Transl Oncol. 2008]
Review Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
Peralta-Leal A, Rodríguez MI, Oliver FJ. Clin Transl Oncol. 2008 Jun; 10(6):318-23.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

Development of PARP inhibitors in oncology.
Development of PARP inhibitors in oncology.
Expert Opin Investig Drugs. 2009 Jan ;18(1):31-43.

PubMed
Anti-inflammatory and antinociceptive effects of Rosmarinus officinalis L. essen...
Anti-inflammatory and antinociceptive effects of Rosmarinus officinalis L. essential oil in experimental animal models.
J Med Food. 2008 Dec ;11(4):741-6.

PubMed
Antioxidant activity of enzymatic extracts from Stellaria dichotoma.
Antioxidant activity of enzymatic extracts from Stellaria dichotoma.
J Med Food. 2008 Dec ;11(4):723-32.

PubMed
Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2bet...
Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.
J Med Chem. 2008 Dec 25 ;51(24):7788-99.

PubMed
Interactions between human glutamate carboxypeptidase II and urea-based inhibito...
Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.
J Med Chem. 2008 Dec 25 ;51(24):7737-43.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: